Palvella Therapeutics, Inc (PVLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has a cash flow conversion efficiency ratio of -0.059x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.85 Million) by net assets ($216.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PVLA market cap for the company's overall valuation and market capitalisation.
Palvella Therapeutics, Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Palvella Therapeutics, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Palvella Therapeutics, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palvella Therapeutics, Inc ranked by their cash flow conversion efficiency. Explore Palvella Therapeutics, Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
0.112x |
|
Hainan Strait Shipping Co Ltd
SHE:002320
|
0.043x |
|
TAG Immobilien AG
XETRA:TEG
|
0.007x |
|
DL E&C Co Ltd
KO:375500
|
0.027x |
|
ODFJELL DRILL.LTD. DL-01
F:OD3
|
0.081x |
|
Simplo Technology Co Ltd
TWO:6121
|
0.027x |
|
Beijing United Information Technology Co Ltd
SHG:603613
|
-0.011x |
|
Aguas Andinas S.A
SN:AGUAS-A
|
0.049x |
Annual Cash Flow Conversion Efficiency for Palvella Therapeutics, Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Palvella Therapeutics, Inc from 2020 to 2025. View Palvella Therapeutics, Inc (PVLA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.98 Million | $-25.01 Million | -0.894x | -416.11% |
| 2024-12-31 | $62.61 Million | $-10.84 Million | -0.173x | -104.90% |
| 2023-12-31 | $-3.88 Million | $-13.70 Million | 3.532x | +451.51% |
| 2022-12-31 | $-23.17 Million | $-14.84 Million | 0.640x | +524.31% |
| 2021-12-31 | $50.76 Million | $-7.66 Million | -0.151x | +89.80% |
| 2020-12-31 | $31.03 Million | $-45.90 Million | -1.479x | -- |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more